[A remarkable effect of K-18 (IgG-melphalan complex) in a case of RAEB with hypoplastic marrow].

Abstract

A 63-year-old male with refractory anemia with excess of blasts (RAEB) and hypoplastic marrow was treated with K-18 (240 mg/day P.O.). On admission, peripheral blood revealed pancytopenia. Bone marrow specimen revealed severe hypocellularity with 18.9% of the blast cells. Ten months later, the blast cells in the bone marrow decreased to 3.8%, and complete remission (CR) was obtained. CR was eight weeks. Duration of response (CR + PR) continued for about eight months. K-18 is an antitumor agent with minimal side effects, and seems to be effective for RAEB with hypoplastic marrow.

• Authors: K Fujikawa, Y Mogi, K Ito, N Tsushima, T Saito, S Ishigaki, N Watanabe, Y Kohgo, T Mikami, Y Niitsu
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 18 Issue 2 Pg. 287-91 (Feb 1991) ISSN: 0385-0684 [Print] Japan
• PMID: 1992922 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Immunoglobulin G
• antineoplastic agent K 18
• Melphalan

Topics

• Anemia, Refractory, with Excess of Blasts (drug therapy)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Marrow Diseases (drug therapy)
• Humans
• Immunoglobulin G (therapeutic use)
• Male
• Melphalan (therapeutic use)
• Middle Aged
• Remission Induction